Clinical trials: Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it.
- Trial name
- NCT05513950
- Testing
- CHF10067 starting dose -- 1000mg (Cohort A), CHF10067 intermediate dose -- 2000mg (Cohort B), CHF10067 high dose -- 3000mg (Cohort C)
- Where
- 9 sites in North Macedonia, Ukraine and 1 more
- Volunteers
- 52 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Treatment of IPF With Laparoscopic Anti-Reflux Surgery
This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital…
- Trial name
- WRAP-IPF (NCT01982968)
- Testing
- Surgery
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Francisco
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Families-At-risk for Interstitial Lung Disease Study
The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia.
- Trial name
- FAR-ILD (NCT03641742)
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Columbia University
Idiopathic Pulmonary Fibrosis
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic…
- Trial name
- NCT04071769
- Testing
- Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Duke University
Scleroderma, Systemic, Sclerosis, Systemic
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of pomalidomide in the treatment of patients with systemic sclerosis with interstitial lung disease.
- Conditions
- Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis
- Trial name
- NCT01559129
- Testing
- Pomalidomide (CC-4047)
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 23 people
- Sponsor
- Celgene
Pulmonary Fibrosis
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial…
- Trial name
- NCT01417156
- Testing
- Nintedanib, Pirfenidoneone
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis, Interstitial Pneumonia
Rituximab in Rheumatoid Arthritis Lung Disease
This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks.
- Trial name
- NCT00578565
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Eric Matteson
Idiopathic Pulmonary Fibrosis
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- SPIRIT (NCT03573505)
- Testing
- BG00011
- Where
- 90 sites in United States, Argentina and 15 more
- Volunteers
- 109 people
- Sponsor
- Biogen
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors.
- Trial name
- NCT02124772
- Testing
- Trametinib, Dabrafenib
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pulmonology Services)
- Trial name
- NCT03386994
- Where
- 31 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis…
- Trial name
- STARSCAPE (NCT04552899)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 360 sites in United States, Argentina and 33 more
- Volunteers
- 665 people
- Sponsor
- Hoffmann-La Roche
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim